Revoking MaNaDr’s licence may have limited impact with its teleconsultation platform.

Date:

Share post:

Telemedicine Revenue Dominates Parent Company’s Sales

Telemedicine revenue accounts for about US$12.8 million or 90.4% of its parent company’s total sales.

Healthcare Provider’s Licence Revoked in Singapore

JUST days before Christmas, MaNaDr Clinic unwrapped a lump of coal in its stocking – confirmation that the healthcare provider’s licence to offer medical services in Singapore had been revoked.

Anticipated Decision

The news was not entirely unexpected. The writing had been on the wall since Oct 24, when the Ministry of Health (MOH) first announced its intention to strip MaNaDr of its licence.

Review Period

The intervening period up to last Friday (Dec 20) allowed the company to present its case to the ministry, outlining why it had fallen short, while MOH deliberated its fate.

Copyright Notice

Copyright SPH Media. All rights reserved.

Conclusion

MaNaDr Clinic’s licence revocation comes as a significant blow to the company, considering the substantial revenue generated from telemedicine services. This development highlights the importance of regulatory compliance in the healthcare industry.

FAQs

Q: What is the reason for MaNaDr Clinic’s licence revocation?

A: The Ministry of Health (MOH) has not publicly disclosed the specific reason for the licence revocation. However, the company was given an opportunity to present its case and propose corrective measures, which were ultimately deemed unsatisfactory.

Q: What is the significance of this development in the healthcare industry?

A: The licence revocation serves as a reminder of the importance of regulatory compliance in the healthcare industry. Telemedicine services, in particular, require stringent adherence to established guidelines and standards to maintain public trust and confidence.

Q: What is the future outlook for MaNaDr Clinic?

A: The company’s fate remains uncertain, with the possibility of reapplication for a healthcare licence in the future. However, the exact timeline and likelihood of success are yet to be determined.

Angela Lee
Angela Lee
Director of Research

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News

- Advertisement -spot_img
- Advertisement -spot_img

Related articles

Singapore Market Unlikely to Repeat 2024’s High; Moderate Returns Expected for 2025

A Year of Two Halves for Singapore Market in 2024 IT HAS been “a year of two halves” for...

The Power of Data Analytics: Why Singapore Companies Need Consulting Insights to Drive Decision-Making

In today's fast-paced and competitive business landscape, data analytics has become a crucial tool for companies to gain...

Singapore’s Blue-Chip Gauge

Singapore Stocks Rise on Friday Market Wrap SINGAPORE shares rose on Friday, with the Straits Times Index (STI) closing marginally...